it’s widely assumed that women are at greater risk for alzheimer’s disease because they typically live longer than men, and age is a risk factor (although not always, since some experience dementia in their forties and fifties). but it’s not the sole reason.
“the data is there that there’s something unique that sets the stage for more alzheimer’s in women,” says einstein. “[but] i don’t think the jury’s in. whatever the case, there certainly are differences in some of the earliest brain changes. women tend to get alzheimer’s disease later than men but once they get it, they progress more quickly. women also maintain their verbal memory longer than men do.”
so, armed with all this knowledge, why is it that every new “breakthrough” drug seems to disappoint? “that’s a very deep and important question that doesn’t have a simple answer,” says einstein. “it may be that people are looking at the wrong problem. alzheimer’s disease research has focused for a long time on plaques, and most of the therapies that are being developed are designed to get rid of, or prevent, the plaques. but plaques may not be causative. we need to think a bit more broadly, but i’m not a clinical trials person for alzheimer’s. i’m more interested in early life interventions and the possibilities that things that we do to ourselves might increase our risk factors. the earlier we are able to identify when changes start and what they are [the earlier] we can come up with lifestyle interventions that could be very important in slowing the progression of change.”
meanwhile, galea is optimistic that a shift is happening, albeit slowly, in how the genders are studied and treated. “i don’t believe we’ll get to where we need to be in terms of our understanding of body and mind until we consider gender as a factor in our studies,” she says. “it’s important to study these differences because it can lead us to better diagnoses and treatments more quickly, no matter your gender.”